[Effects of simultaneous use of Cerebrolysin and alteplase on hemorrhagic transformation of brain infarction and functional outcome in stroke patients: CEREHETIS, a randomized, multicenter pilot trial].

Khasanova DR, Kalinin MN

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2023Cited by 5 (Europe PMC)

PMID37682097DOI10.17116/jnevro202312308260PepBankPUB-37682097

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acute stroke patients, adding Cerebrolysin to Alteplase reduced symptomatic hemorrhagic transformation versus Alteplase and baseline therapy alone.
In plain wordsIn stroke patients, adding Cerebrolysin to Alteplase reduced symptomatic brain bleeding compared with Alteplase and baseline therapy alone.
Peptide
Cerebrolysin
Outcome
DecreaseSymptomatic hemorrhagic transformation
Study
n = 341
Comparator
Alteplase and baseline therapy alone
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
30 mL · intravenous · 14 consecutive daysAs given in this study (human).
Measurements
Odds ratio
0.248
symptomatic hemorrhagic transformation
Confidence interval
0.072 to 0.851
95% CI
P value
0.019
symptomatic hemorrhagic transformation
Source sentences
Summary
Treatment with Cerebrolysin resulted in a significant reduction of the symptomatic HT rate with an odds ratio of 0.248 (95% CI: 0.072-0.851; p=0.019).
2 context sentences(design, population, supporting numbers)
Summary · context
The intervention group (n=126) was treated with Cerebrolysin infusion (30 mL) started simultaneously with Alteplase (0.9 mg/kg) via a separate IV line.
Summary · context
The control group (n=215) received only Alteplase and the baseline therapy.
Report a problemFND-3768209701
02HumanRandomized controlled trialEfficacy outcome
In acute stroke patients, adding Cerebrolysin to Alteplase reduced NIHSS scores on day 14 versus Alteplase and baseline therapy alone.
In plain wordsIn stroke patients, adding Cerebrolysin to Alteplase lowered neurological deficit scores on day 14 compared with Alteplase and baseline therapy alone.
Peptide
Cerebrolysin
Outcome
DecreaseNIHSS score on day 14
Study
n = 341
Comparator
Alteplase and baseline therapy alone
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
30 mL · intravenous · 14 consecutive daysAs given in this study (human).
Measurements
P value
0.045
NIHSS score day 14
Source sentences
Summary
On day 14, the intervention group showed a significant reduction in the NIHSS score (p=0.045).
2 context sentences(design, population, supporting numbers)
Summary · context
The intervention group (n=126) was treated with Cerebrolysin infusion (30 mL) started simultaneously with Alteplase (0.9 mg/kg) via a separate IV line.
Summary · context
The control group (n=215) received only Alteplase and the baseline therapy.
Report a problemFND-3768209703
03HumanRandomized controlled trialEfficacy outcome
In acute stroke patients, adding Cerebrolysin to Alteplase did not significantly change day 90 mRS scores versus control, despite an improvement trend.
In plain wordsIn stroke patients, adding Cerebrolysin to Alteplase did not change disability scores significantly compared with control at day 90.
Peptide
Cerebrolysin
Outcome
No significant changemRS score on day 90
Study
n = 341
Comparator
Alteplase and baseline therapy alone
Analysis
Secondary
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
30 mL · intravenous · 14 consecutive daysAs given in this study (human).
Source sentences
Summary
However, no difference in the mRS score was observed on day 90, but there was a trend towards its improvement.
2 context sentences(design, population, supporting numbers)
Summary · context
The intervention group (n=126) was treated with Cerebrolysin infusion (30 mL) started simultaneously with Alteplase (0.9 mg/kg) via a separate IV line.
Summary · context
The control group (n=215) received only Alteplase and the baseline therapy.
Report a problemFND-3768209704
04HumanRandomized controlled trialSafety outcome
In acute stroke patients receiving Cerebrolysin with Alteplase, no serious adverse events related to Cerebrolysin were observed.
In plain wordsIn stroke patients receiving Cerebrolysin with Alteplase, no serious adverse events related to Cerebrolysin occurred.
Peptide
Cerebrolysin
Outcome
Not applicableCerebrolysin-related serious adverse events
Study
n = 126
Analysis
Secondary
Outcome group
Adverse events · Nervous system and cognition
Studied dose
30 mL · intravenous · 14 consecutive daysAs given in this study (human).
Source sentences
Summary
No serious adverse events related to Cerebrolysin were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
The intervention group (n=126) was treated with Cerebrolysin infusion (30 mL) started simultaneously with Alteplase (0.9 mg/kg) via a separate IV line.
Summary · context
The control group (n=215) received only Alteplase and the baseline therapy.
Report a problemFND-3768209702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.